Roche wins reprieve as Novartis biosimilar delayed in US Ruby Khatun Khatun5 May 2018 9:30 AM ISTLONDON/ZURICH: Roche has won a reprieve from an expected wave of cheaper versions of its biotech cancer drugs as U.S. regulators knocked back a...
Biocon gets 7 USFDA observations for Bengaluru drug facility Ruby Khatun Khatun4 May 2018 11:00 AM ISTNew Delhi: Biotechnology major Biocon said the US health regulator has made seven observations after inspection of its sterile drug product...
UBS Principal sells 5.44 percent stake in Fortis Healthcare for Rs 443 crore Ruby Khatun Khatun4 May 2018 10:30 AM ISTNew Delhi: UBS Principal Capital Asia offloaded 5.44 percent stake in Fortis Healthcare for over Rs 443 crore through an open market...
Strides Shasun gets USFDA approval for generic Sensipar tablets Ruby Khatun Khatun4 May 2018 10:15 AM ISTNew Delhi: Drug firm Strides Shasun said its wholly-owned subsidiary Strides Pharma Global has received approval from the US health regulator for...
Google, Fitbit collaboration to spur digital healthcare Ruby Khatun Khatun4 May 2018 10:01 AM ISTNew Delhi: Taking another stride in the digital healthcare segment, Google announced its collaboration with Fitbit to help drive positive health...
Regulator says Samsung Biologics breaches accounting rules Ruby Khatun Khatun4 May 2018 9:45 AM ISTSEOUL: A South Korean regulator said Samsung Biologics Co. breached accounting rules in a preliminary finding that could deal a big blow to the...
Migraine drug delay would compound Teva's troubles Ruby Khatun Khatun4 May 2018 9:30 AM ISTTEL AVIV: Teva Pharmaceutical Industries is counting on its new migraine treatment to haul it out of the doldrums. But a possible delay in U.S....
Manipal-led bid for Fortis faces objections: Sources Ruby Khatun Khatun3 May 2018 3:32 PM ISTMUMBAI: Two major investors in Fortis Healthcare, who have concerns over the bidding process for the cash-strapped Indian hospital operator, plan to...
Ajanta Pharma Q4 profit down 17 percent at Rs 94 crore Ruby Khatun Khatun3 May 2018 10:30 AM ISTNew Delhi: Ajanta Pharma on Wednesday reported 17.13 percent decline in profit after tax (PAT) at Rs 94.49 crore for the quarter ended March 31, 2018,...
Cipla gets USFDA approval for generic equivalents of Vazculep, Aromasin Ruby Khatun Khatun3 May 2018 10:10 AM ISTNew Delhi: Drug major Cipla has received final approval from the US health regulator for the generic equivalent of Avadel's Vazculep, West Ward Pharm...
India rejects US request on price caps on medical devices: Sources Ruby Khatun Khatun3 May 2018 10:00 AM ISTNew Delhi: India has told the United States it won't abstain from capping prices for more medical devices, regardless of pressure to rethink its...
Novartis biosimilar cancer drug hits US regulatory bump Ruby Khatun Khatun3 May 2018 9:45 AM ISTZURICH: Novartis AG said its biosimilar version of rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis had not...
